Literature DB >> 32343209

Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis.

Iris Y Zhou1, Veronica Clavijo Jordan1, Nicholas J Rotile1, Eman Akam1, Smitha Krishnan1, Gunisha Arora1, Hema Krishnan1, Hannah Slattery1, Noah Warner1, Nathaniel Mercaldo1, Christian T Farrar1, Jeremy Wellen1, Robert Martinez1, Franklin Schlerman1, Kenneth K Tanabe1, Bryan C Fuchs1, Peter Caravan1.   

Abstract

Background Liver biopsy is the reference standard to diagnose nonalcoholic steatohepatitis (NASH) but is invasive with potential complications. Purpose To evaluate molecular MRI with type 1 collagen-specific probe EP-3533 and allysine-targeted fibrogenesis probe Gd-Hyd, MR elastography, and native T1 to characterize fibrosis and to assess treatment response in a rat model of NASH. Materials and Methods MRI was performed prospectively (June-November 2018) in six groups of male Wistar rats (a) age- and (b) weight-matched animals received standard chow (n = 12 per group); (c) received choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD) for 6 weeks or (d) 9 weeks (n = 8 per group); (e) were fed 6 weeks of CDAHFD and switched to standard chow for 3 weeks (n = 12); (f) were fed CDAHFD for 9 weeks with daily treatment of elafibranor beginning at week 6 (n = 14). Differences in imaging measurements and tissue analyses among groups were tested with one-way analysis of variance. The ability of each imaging measurement to stage fibrosis was quantified by using area under the receiver operating characteristic curve (AUC) with quantitative digital pathology (collagen proportionate area [CPA]) as reference standard. Optimal cutoff values for distinguishing advanced fibrosis were used to assess treatment response. Results AUC for distinguishing fibrotic (CPA >4.8%) from nonfibrotic (CPA ≤4.8%) livers was 0.95 (95% confidence interval [CI]: 0.91, 1.00) for EP-3533, followed by native T1, Gd-Hyd, and MR elastography with AUCs of 0.90 (95% CI: 0.83, 0.98), 0.84 (95% CI: 0.74, 0.95), and 0.65 (95% CI: 0.51, 0.79), respectively. AUCs for discriminating advanced fibrosis (CPA >10.3%) were 0.86 (95% CI: 0.76, 0.97), 0.96 (95% CI: 0.90, 1.01), 0.84 (95% CI: 0.70, 0.98), and 0.74 (95% CI: 0.63, 0.86) for EP-3533, Gd-Hyd, MR elastography, and native T1, respectively. Gd-Hyd MRI had the highest accuracy (24 of 26, 92%; 95% CI: 75%, 99%) in identifying responders and nonresponders in the treated groups compared with MR elastography (23 of 26, 88%; 95% CI: 70%, 98%), EP-3533 (20 of 26, 77%; 95% CI: 56%, 91%), and native T1 (14 of 26, 54%; 95% CI: 33%, 73%). Conclusion Collagen-targeted molecular MRI most accurately detected early onset of fibrosis, whereas the fibrogenesis probe Gd-Hyd proved most accurate for detecting treatment response. © RSNA, 2020 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32343209      PMCID: PMC7325703          DOI: 10.1148/radiol.2020192118

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  39 in total

1.  Liquid chromatographic determination of hydroxyproline in tissue samples.

Authors:  Paul R Hutson; Mark E Crawford; Ronald L Sorkness
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-07-05       Impact factor: 3.205

2.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

3.  Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease.

Authors:  Elena Buzzetti; Andrew Hall; Mattias Ekstedt; Roberta Manuguerra; Marta Guerrero Misas; Claudia Covelli; Gioacchino Leandro; TuVinh Luong; Stergios Kechagias; Emanuel K Manesis; Massimo Pinzani; Amar P Dhillon; Emmanuel A Tsochatzis
Journal:  Aliment Pharmacol Ther       Date:  2019-03-18       Impact factor: 8.171

4.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  J Hepatol       Date:  2017-08-10       Impact factor: 25.083

5.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

Authors:  G Marchesini; M Brizi; G Bianchi; S Tomassetti; E Bugianesi; M Lenzi; A J McCullough; S Natale; G Forlani; N Melchionda
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

6.  Molecular MRI of collagen to diagnose and stage liver fibrosis.

Authors:  Bryan C Fuchs; Huifang Wang; Yan Yang; Lan Wei; Miloslav Polasek; Daniel T Schühle; Gregory Y Lauwers; Ashfaq Parkar; Anthony J Sinskey; Kenneth K Tanabe; Peter Caravan
Journal:  J Hepatol       Date:  2013-07-06       Impact factor: 25.083

7.  Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats.

Authors:  M Yasuda; I Shimizu; M Shiba; S Ito
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

Review 8.  Detection of lipid in abdominal tissues with opposed-phase gradient-echo images at 1.5 T: techniques and diagnostic importance.

Authors:  E K Outwater; R Blasbalg; E S Siegelman; M Vala
Journal:  Radiographics       Date:  1998 Nov-Dec       Impact factor: 5.333

9.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Authors:  Laurent Sandrin; Bertrand Fourquet; Jean-Michel Hasquenoph; Sylvain Yon; Céline Fournier; Frédéric Mal; Christos Christidis; Marianne Ziol; Bruno Poulet; Farad Kazemi; Michel Beaugrand; Robert Palau
Journal:  Ultrasound Med Biol       Date:  2003-12       Impact factor: 2.998

10.  Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.

Authors:  Michael Pavlides; Rajarshi Banerjee; Joanne Sellwood; Catherine J Kelly; Matthew D Robson; Jonathan C Booth; Jane Collier; Stefan Neubauer; Eleanor Barnes
Journal:  J Hepatol       Date:  2015-11-10       Impact factor: 25.083

View more
  5 in total

Review 1.  Advances in functional and molecular MRI technologies in chronic liver diseases.

Authors:  Iris Y Zhou; Onofrio A Catalano; Peter Caravan
Journal:  J Hepatol       Date:  2020-06-22       Impact factor: 25.083

Review 2.  Collagen-targeted molecular imaging in diffuse liver diseases.

Authors:  Iris Y Zhou; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan
Journal:  Abdom Radiol (NY)       Date:  2020-07-31

3.  Lysyl oxidase regulation and protein aldehydes in the injured newborn lung.

Authors:  Ying Zhong; Rose C Mahoney; Zehedina Khatun; Howard H Chen; Christopher T Nguyen; Peter Caravan; Jesse D Roberts
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-08       Impact factor: 5.464

4.  Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.

Authors:  Philip A Waghorn; Diego S Ferreira; Derek J Erstad; Nicholas J Rotile; Ricard Masia; Chloe M Jones; Chuantao Tu; Mozhdeh Sojoodi; Yin-Ching I Chen; Franklin Schlerman; Jeremy Wellen; Robert V P Martinez; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

Review 5.  Survey of water proton longitudinal relaxation in liver in vivo.

Authors:  John Charles Waterton
Journal:  MAGMA       Date:  2021-05-12       Impact factor: 2.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.